Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study

• Published in: BMJ open 2022-04, Vol.12 (4), p.e055454-e055454
• Main Authors: Fontaine, Jennifer, Chin, Evelyn, Provencher, Jean-François, Rainone, Anthony, Wazzan, Dana, Roy, Carmella, Rej, Soham, Lordkipanidze, Marie, Dagenais-Beaulé, Vincent
• Format: Article
• Language: English
• Subjects: Adult; antipsychotic agents; Antipsychotic Agents - adverse effects; Antipsychotics; Benzodiazepines; Bipolar disorder; Blood Glucose; Blood pressure; Canada; cardiometabolic side effects; Cardiovascular Diseases; Cardiovascular Medicine; Cardiovascular system; Cross-Sectional Studies; drug-related side effects and adverse reactions; Glucose; Glycated Hemoglobin A; guideline adherence; Health risks; Humans; Hypertension; Inpatients; Metabolism; Psychotropic drugs; Quetiapine Fumarate; Schizophrenia; Side effects
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-055454

ObjectivesThis study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting.DesignCross-sectional study.SettingThe psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada.Participants402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016.Primary outcome measuresWe assessed the proportion of cardiometabolic parameters monitored.Secondary outcome measuresWe identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results.ResultsOnly 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring.ConclusionsThis study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring.